Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma (Phase II)
2016-001599-31Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab and ipilimumab in pleural mesothelioma, sponsored by Netherlands Cancer Institute. Primary endpoint: Disease control rate at 12 weeks. Started Aug 2016; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2016-001599-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001599-31.